Iovance Biotherapeutics, Inc. (IOVA)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$14.09-0.35%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Iovance Biotherapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	128.45M
EPS	—	-0.076
Annual ending 2026-12-31
Revenue	—	414.74M
EPS	—	-0.444
Annual ending 2027-12-31
Revenue	—	593.63M
EPS	—	-0.171

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Improve operating income and cash flow	The company is improving cost discipline, reducing operating losses from -$114M to -$81M.	Intact	Operating income worse than -$81M or cash flow worse than -$72M	Operating income: $-51.905M FY2026-Q2; GAAP. Published target: Operating income better than -$81M and cash flow better than -$72M. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 6, 2026-51,905,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: b960ed5c-3f2a-4496-bdfd-2a8480037f37. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 quarters (2026-Q1 and 2026-Q2). Gross margin was approximately 56% in 2Q26, supported by operational improvements and cost discipline initiatives. Management reiterated focus on cost reductions and profitability. The trajectory shows delivering progress on cost discipline aligned with revenue growth. Delivery assessment Oct 24, 2026
Meet 2Q26 revenue guidance of $86M-$88M	Quarterly revenue guidance for 2Q26 is $86M-$88M, showing steady progress.	Intact	2Q26 revenue falls below $86M	Revenue: $99.313M FY2026-Q2; GAAP. Published target: $86M-$88M revenue. The target does not explicitly identify fiscal versus calendar quarters. Source published Aug 6, 202699,313,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: b960ed5c-3f2a-4496-bdfd-2a8480037f37. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 3 quarters including 2026-Q1 and 2026-Q2. Actual 2Q26 revenue was $99.3M, exceeding the $86M-$88M guidance by over 10%. This confirms delivery on the 2Q26 revenue target with strong growth from $71.4M in 2026-Q1 to $99.3M in 2026-Q2. Delivery assessment Oct 24, 2026
Maintain regulatory approvals and trial progress	Regulatory approvals boost confidence in its cancer immunotherapy products.	Intact	Loss of key regulatory approvals or trial setbacks	Qualitative: Long-term response data for Amtagvi in first-line melanoma supports pipeline advancement News highlights long-term response for Amtagvi in first-line melanoma, supporting the advancement of clinical trials and regulatory approvals. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve FY26 revenue of $350M-$370M	A primary condition in Iovance Biotherapeutics, Inc.'s published investment case. The stated target is $350M-$370M total revenue.	Intact	Total revenue falls below $350M in FY26	Revenue: $99.313M FY2026-Q2; GAAP. Published target: $350M-$370M total revenue. Target period is not explicitly aligned with this observation. Source published Aug 6, 202699,313,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: b960ed5c-3f2a-4496-bdfd-2a8480037f37. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 quarters including 2026-Q1, 2026-Q2, and a 2026-09-29 update. Revenue grew from $71.4M in 2026-Q1 to $99.3M in 2026-Q2, exceeding prior guidance by >10%. The company raised FY26 revenue guidance midpoint by $55M to $415M, reflecting nearly 60% annual growth. The trajectory is delivering with strong demand and upward revisions. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.17

$-0.31 → $-0.17 · observed estimates

FY2027 revenue$0.59B

$0.50B → $0.59B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.31	$496,226,881	6 / 6
2026-07-25	$-0.31	$496,226,881	6 / 6
2026-07-26	$-0.32	$496,276,260	7 / 8
2026-07-27	$-0.32	$496,276,260	7 / 8
2026-07-28	$-0.31	$496,226,881	6 / 6
2026-07-29	$-0.32	$496,276,260	7 / 8
2026-07-30	$-0.32	$496,276,260	7 / 8
2026-07-31	$-0.32	$496,536,360	7 / 8
2026-08-01	$-0.31	$496,486,985	6 / 6
2026-08-02	$-0.32	$496,536,360	7 / 8
2026-08-03	$-0.32	$496,536,360	7 / 8
2026-08-04	$-0.31	$496,486,985	6 / 6
2026-08-05	$-0.32	$496,536,360	7 / 8
2026-08-06	$-0.32	$496,536,360	7 / 8
2026-08-07	$-0.31	$496,486,985	6 / 6
2026-08-08	$-0.31	$496,486,985	6 / 6
2026-08-09	$-0.28	$536,111,610	7 / 8
2026-08-10	$-0.31	$496,486,985	6 / 6
2026-08-12	$-0.31	$496,486,985	6 / 6
2026-08-13	$-0.31	$496,486,985	6 / 6
2026-08-14	$-0.31	$496,486,985	6 / 6
2026-08-15	$-0.31	$496,486,985	6 / 6
2026-08-16	$-0.31	$496,486,985	6 / 6
2026-08-17	$-0.31	$496,486,985	6 / 6
2026-08-18	$-0.31	$496,486,985	6 / 6
2026-08-19	$-0.31	$496,486,985	6 / 6
2026-08-20	$-0.26	$555,100,610	6 / 6
2026-08-21	$-0.23	$569,314,292	6 / 6
2026-08-22	$-0.23	$569,314,292	6 / 6
2026-08-23	$-0.23	$569,314,292	6 / 6
2026-08-24	$-0.23	$569,314,292	6 / 6
2026-08-25	$-0.23	$569,314,292	6 / 6
2026-08-26	$-0.25	$557,439,292	5 / 6
2026-08-27	$-0.25	$557,439,292	5 / 6
2026-08-28	$-0.25	$557,439,292	6 / 6
2026-08-29	$-0.25	$557,439,292	6 / 6
2026-08-30	$-0.25	$557,439,292	6 / 6
2026-08-31	$-0.25	$557,439,292	6 / 6
2026-09-01	$-0.25	$557,439,292	6 / 6
2026-09-02	$-0.25	$557,439,292	6 / 6
2026-09-03	$-0.25	$557,439,292	6 / 6
2026-09-04	$-0.25	$557,439,292	6 / 6
2026-09-05	$-0.25	$557,439,292	6 / 6
2026-09-06	$-0.25	$557,439,292	6 / 6
2026-09-07	$-0.25	$557,439,292	6 / 6
2026-09-08	$-0.25	$557,439,292	6 / 6
2026-09-09	$-0.25	$557,439,292	6 / 6
2026-09-10	$-0.25	$557,439,292	6 / 6
2026-09-11	$-0.25	$557,439,292	6 / 6
2026-09-12	$-0.25	$557,439,292	6 / 6
2026-09-13	$-0.25	$557,439,292	6 / 6
2026-09-14	$-0.25	$557,439,292	6 / 6
2026-09-15	$-0.25	$557,439,292	6 / 6
2026-09-16	$-0.25	$557,439,292	6 / 6
2026-09-17	$-0.25	$557,439,292	6 / 6
2026-09-18	$-0.23	$557,439,292	6 / 6
2026-09-19	$-0.23	$557,439,292	6 / 6
2026-09-20	$-0.23	$557,439,292	6 / 6
2026-09-21	$-0.23	$557,439,292	6 / 6
2026-09-22	$-0.23	$557,439,292	6 / 6
2026-09-23	$-0.23	$557,439,292	6 / 6
2026-09-24	$-0.23	$557,439,292	6 / 6
2026-09-25	$-0.23	$557,439,292	6 / 6
2026-09-26	$-0.23	$561,034,482	6 / 7
2026-09-27	$-0.23	$561,034,482	6 / 7
2026-09-28	$-0.23	$561,034,482	6 / 7
2026-09-29	$-0.23	$561,034,482	6 / 7
2026-09-30	$-0.21	$572,634,482	6 / 7
2026-10-01	$-0.21	$575,242,837	6 / 7
2026-10-02	$-0.21	$575,244,259	6 / 7
2026-10-03	$-0.21	$575,244,259	6 / 7
2026-10-04	$-0.21	$575,244,259	6 / 7
2026-10-05	$-0.21	$575,244,259	6 / 7
2026-10-06	$-0.21	$575,244,259	6 / 7
2026-10-07	$-0.21	$575,244,259	6 / 7
2026-10-08	$-0.21	$575,244,259	6 / 7
2026-10-09	$-0.19	$587,786,704	6 / 7
2026-10-10	$-0.19	$587,786,704	6 / 7
2026-10-11	$-0.19	$587,786,704	6 / 7
2026-10-12	$-0.19	$587,786,704	6 / 7
2026-10-13	$-0.19	$587,786,704	6 / 7
2026-10-14	$-0.17	$593,631,148	6 / 7
2026-10-15	$-0.17	$593,631,148	6 / 7
2026-10-16	$-0.17	$593,631,148	6 / 7
2026-10-17	$-0.17	$593,631,148	6 / 7
2026-10-18	$-0.17	$593,629,722	6 / 7
2026-10-19	$-0.17	$593,629,722	6 / 7
2026-10-20	$-0.17	$593,629,722	6 / 7
2026-10-21	$-0.17	$593,629,722	6 / 7
2026-10-22	$-0.17	$593,629,722	6 / 7
2026-10-23	$-0.17	$593,629,722	6 / 7
2026-10-24	$-0.17	$593,629,722	6 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	8	3
2026-06-01	8	2
2026-07-01	8	2
2026-08-01	7	2
2026-09-01	8	2
2026-10-01	8	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 8 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades4 maintains

Recent actions · Sep 25–Oct 24 · 4 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

BarclaysOct 13 · prior Sep 17

$15.00 → $18.00+20.0%

Robert W. BairdOct 8 · prior Aug 7

$6.00 → $11.00+83.3%

Wells FargoSep 30 · prior Jun 1

$5.00 → $18.00+260.0%

JefferiesSep 29

$16.00New observation · no comparable prior

H.C. WainwrightSep 29

$20.00New observation · no comparable prior

$0$11.00$22.00

3 raises · 0 cuts · 0 unchanged · 2 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Improve operating income and cash flowOperating income: $-51.905M
Meet 2Q26 revenue guidance of $86M-$88MRevenue: $99.313M
Achieve FY26 revenue of $350M-$370MRevenue: $99.313M

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.0%Typical daily move · historical

Downside history

-39.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Iovance Biotherapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

IOVA is a high-risk growth business, not yet a proven profitable compounder. Its long-term thesis is intact, supported by recent revenue growth and an expanding Amtagvi treatment-center network, though the evidence carries medium confidence.

What's priced into Iovance Biotherapeutics, Inc.

The snapshot characterizes IOVA as cheap versus peers, with no premium indicated, but confidence in that valuation view is low. The expectations gap is negative, so the market appears to assume more than the model’s base case; no specific market expectations are provided.

What the fundamentals likely do

Near term, revenue execution has been strong: second-quarter revenue was above guidance, and the company raised its FY26 revenue midpoint. The treatment-center network is expanding, while global regulatory work continues; profitability remains a challenge, and a guidance cut is a key risk.

What Iovance Biotherapeutics, Inc. hinges on

Over the next few quarters, the thesis depends on meeting FY26 revenue guidance and continuing to expand Amtagvi’s reach. A guidance cut or weaker economic signals could weigh on the setup, while strength among major Healthcare peers could support the sector backdrop.